New trials, publications, preprints and grants on this target, month by month.
Trial
CAR-T Immunotherapy Targeting CD19- ALL
1 Jul 2027· PHASE1_PHASE2 · NOT_YET_RECRUITING· CTGOV
Trial
Multi-CAR-T Cells Targeting B Cell Lymphomas
1 Jun 2027· PHASE1_PHASE2 · NOT_YET_RECRUITING· CTGOV
Trial
CD19/22 Bi-specific CAR-T Cell Therapy
1 Jun 2027· PHASE1_PHASE2 · NOT_YET_RECRUITING· CTGOV
Trial
REGN9220 in Combination With Odronextamab in Adult Participants With Relapsed or Refractory Aggressive B-Cell Non-Hodgkin Lymphomas (BCNHLs)
7 Dec 2026· PHASE1_PHASE2 · NOT_YET_RECRUITING· CTGOV
Trial
Venetoclax Plus Inotuzumab Reduced-Intensity Induction Sequentially Followed by Blinatumomab in B-ALL
30 Nov 2026· NA · NOT_YET_RECRUITING· CTGOV
Publication
Immunohistochemical Classification and Prognostic Significance of Germinal Center-like and Memory Cell-like Subtypes of Follicular Lymphoma Using FOXP1, LMO2, CD22, and MUM1.
26 Sept 2026· International journal of molecular sciences· PUBMED
Publication
A Phase I/II Trial of Anti-CD22/CD19 CAR-T Cell Therapy, CART2219.1, in Adult and Pediatric Relapsed/Refractory B-ALL.
21 Sept 2026· Blood cancer discovery· PUBMED
Publication
Bicistronic CD19/CD22 CAR T-Cell Therapy in Pediatric B-Cell Acute Lymphoblastic Leukemia: A Nonrandomized Clinical Trial.
3 Sept 2026· JAMA oncology· PUBMED
Trial
A Phase 1/2 Study of UB-VV400 With Rapamycin in Relapsed/Refractory B-cell Malignancies
1 Sept 2026· PHASE1_PHASE2 · RECRUITING· CTGOV
Publication
CD22 regulates Aβ clearance in microglia through INPP5D signaling.
28 Jul 2026· Frontiers in cellular neuroscience· PUBMED
Publication
Secondary peripheral T-cell lymphoma in a patient with DLBCL harboring BLM mutation following CD19/CD22 bispecific CAR-T cell therapy.
8 Jul 2026· Journal for immunotherapy of cancer· PUBMED
Publication
Anti-CD19/CD22 CAR T cells in refractory immune thrombocytopenia of paediatric systemic lupus erythematosus.
7 Jul 2026· Annals of the rheumatic diseases· PUBMED
Trial
CD22 CAR T-cells to Extend Remission Following Commercial CD19 CAR T-cells in Children, Adolescents, and Adults With Relapsed/Refractory B-cell Acute Lymphoblastic Leukemia
16 Jun 2026· PHASE2 · RECRUITING· CTGOV
Publication
SM03, a non-depleting anti-CD22 antibody, modulates B cell activation and immune crosstalk to attenuate autoimmunity.
10 Jun 2026· Journal of translational autoimmunity· PUBMED
Publication
CD19/CD22 bivalent CAR T cells in children, adolescents and young adults with B-ALL: final phase 1 trial results.
5 Jun 2026· Journal for immunotherapy of cancer· PUBMED
Publication
Long-term complete remission and minimal side effects after CD19/CD22 CAR-T cell cocktail therapy in a living donor with DLBCL: A rare case report.
2 Jun 2026· Cell transplantation· PUBMED
Trial
4SCAR-T Therapy Post CD19-targeted Immunotherapy
1 Jun 2026· PHASE1_PHASE2 · TERMINATED· CTGOV
Publication
Unraveling cellular and molecular mechanisms of relapse in CD19/CD22 dual-targeting chimeric antigen receptor T-cell therapy for B-cell acute lymphoblastic leukemia.
29 May 2026· Leukemia· PUBMED
Trial
Dual-Targeted Umbilical Cord Blood CAR-T Cells Against CD19 and CD22 for the Treatment of Relapsed or Refractory Acute B-Cell Lymphoblastic Leukemia
13 May 2026· PHASE1 · RECRUITING· CTGOV
Publication
PD-L1-armored CD19/CD22 dual-targeted CAR-T cell co-infusion bridging to allogeneic hematopoietic stem cell transplantation achieves 7-year sustained remission in an adult patient with early relapsed, chemorefractory B-cell acute lymphoblastic leukemia: a case report.
27 Apr 2026· Frontiers in immunology· PUBMED
Publication
CD22-targeted immunotherapy for B-cell acute lymphoblastic leukemia progressing following CD19-targeted immunotherapy.
10 Apr 2026· NPJ precision oncology· PUBMED
Publication
Long-term outcomes of co-administration of CD19 and CD22 CAR-T cell therapy in pediatric patients with relapsed/refractory Philadelphia chromosome-positive acute lymphoblastic leukemia.
10 Apr 2026· Frontiers in medicine· PUBMED
Publication
TrkB promotes the neuronal secretion of soluble Siglec-2 (CD22) to mitigate microglial activation and alleviate depression-like behaviors in male mice.
1 Apr 2026· Molecular psychiatry· PUBMED
Publication
Disrupting CD22-cis-ligand interactions ameliorates type 1 diabetes and graft rejection by expanding regulatory B cells.
24 Mar 2026· PLoS biology· PUBMED
Trial
Safety, Tolerability, and Pharmacokinetics of Donor-derived CD19 CAR Therapy Bridged Allo-HSCT and Sequential Donor-derived CD22 CAR Therapy for r/r B-ALL: a Clinical Trial
15 Mar 2026· PHASE1 · RECRUITING· CTGOV
Trial
CD19/ CD22 Bispecific CAR-T Cell Therapy for Relapsed/ Refractory Large B-cell Lymphoma
10 Mar 2026· PHASE2 · COMPLETED· CTGOV
Publication
Ten-year experience of CD22 CAR T cells for children and young adults with B-cell acute lymphoblastic leukemia.
10 Mar 2026· Blood advances· PUBMED
Trial
Adaptive Dual-Target CAR-T Cells for Relapsed or Refractory Hematologic Malignancies
2 Mar 2026· PHASE1_PHASE2 · RECRUITING· CTGOV
Trial
Clinical Study of Novel TLR2-Containing CAR-T Cells Targeting CD19 and CD22 for Relapsed/Refractory B-ALL and NHL
15 Feb 2026· EARLY_PHASE1 · NOT_YET_RECRUITING· CTGOV
Publication
Long-term follow-up demonstrates the curative potential of dual CD19/CD22 CAR-T-cell therapy alone or combined with autologous stem cell transplantation in TP53-altered relapsed/refractory B-cell non-Hodgkin lymphoma.
13 Feb 2026· Signal transduction and targeted therapy· PUBMED